Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...
pharmaphorum5d
Two biotechs target dry eye disease after Novartis' Xiidra problems
AZR-MD-001, met its primary endpoints of showing improvements in both the signs and symptoms of dry eye disease caused by Meibomian gland dysfunction (MGD) reaching statistical significance ...
ETF Daily News4d
130,454 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Mutual of America Capital Management LLC
The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. Receive ...
pharmaphorum2d
Aldeyra spies FDA filing ahead for dry eye drug reproxalap
NOV03 is being reviewed as a treatment for the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction (MGD), a group which is estimated to account for the majority ...
Daily1d
Hyperosmolar patients significantly increased variation in light scatter following cataract surgery: Study
Along with symptoms of ocular surface disease, slit-lamp examination included corneal staining (0–3), tear film breakup time ...